Evidence map›Paper›PMID 38653751›Full record

ArticleEye (London, England)2024

Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4.

Andrea Montesel, Raheeba Pakeer Muhammed, Swati Chandak, Dimitrios Kazantzis, Sridevi Thottarath, Shruti Chandra, Victor Chong, Benjamin J L Burton, Geeta Menon, Ian Pearce and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Andrea MonteselNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Raheeba Pakeer MuhammedNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Swati ChandakNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-8255-6253
Dimitrios KazantzisNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-4145-8144
Sridevi ThottarathNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Shruti ChandraNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-2634-9775
Victor ChongInstitute of Ophthalmology, University College London, London, UK.ORCID http://orcid.org/0000-0002-7693-522X
Benjamin J L BurtonJames Paget University Hospitals NHS Foundation Trust, Norfolk, UK.ORCID http://orcid.org/0000-0001-9579-9078
Geeta MenonFrimley Health NHS Foundation Trust, Surrey, UK.
Ian PearceLiverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Martin McKibbinLeeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID http://orcid.org/0000-0003-4388-243X
Ajay KotagiriSouth Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
James TalksNewcastle Hospitals NHS Foundation Trust, Newcastle, UK.
Anna GrabowskaKing's College Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-3053-2142
Faruque GhanchiBradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
Richard GaleYork Teaching Hospital NHS Foundation Trust, York, UK.
Andrea GianiBoehringer Ingelheim, Rhein, Germany.
Taffeta Ching Ning YamaguchiBoehringer Ingelheim, Rhein, Germany.
Sobha SivaprasadNIHR Moorfields Biomedical Research Centre and Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London, UK. sobha.sivaprasad@nhs.net.ORCID http://orcid.org/0000-0001-8952-0659

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the prevalence of subretinal transient hyporeflectivity (STHR) in exudative neovascular age-related macular degeneration (nAMD) and its response to a loading phase of aflibercept.

methodsOptical coherence tomography (OCT) scans of treatment-naïve nAMD patients captured at baseline and after a loading phase of aflibercept were graded for presence of STHR, defined as a small, well-defined, round, subretinal, hyporeflective area, delimited between the ellipsoid zone (EZ) and the retinal pigmented epithelium/Bruch membrane complex. OCT parameters recorded were macular neovascularisation (MNV) subtypes, location of retinal fluids (subretinal fluid, SRF and intraretinal fluid, IRF), central retinal and choroidal thickness. Response was defined as absence of IRF and SRF. Factors associated with completely resolved STHR versus persistent STHR post-loading phase were compared.

results2039 eyes of 1901 patients were analysed. STHR was observed in 79 eyes of 78 patients, with an estimated prevalence of 3.87% (95% CI 3.08-4.81%). STHR were seen in 44 type 1 MNV (56%), 27 with type 2 (34%), and 8 with type 3 (10%). At baseline, a total of 303 STHR were present, ranging between 1-22 per eye. The total number of STHR reduced significantly after the loading phase to 173 (p = 0.002). Complete disappearance of STHR was seen in 44 eyes (56%) and persistent STHR in the rest (44%).

conclusionsSTHR may represent a marker of low-grade exudation in nAMD eyes with good response to a loading phase of aflibercept. However, its potential role as an independent nAMD activity biomarker is limited as most resolve after the loading phase.

Indexed as

Angiogenesis InhibitorsIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsSubretinal FluidTomography, Optical CoherenceVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleFluorescein AngiographyHumansMaleRetinaRetinal Pigment EpitheliumafliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID38653751
PMCPMC11385578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.